King completes Elan deal
Executive Summary
King completes acquisition of Elan's primary care business, including muscle relaxant Skelaxin and insomnia agent Sonata. King initially refused to complete the deal in light of Federal Trade Commission inquiry into Skelaxin "Orange Book" patent listings (1"The Pink Sheet" May 26, 2003, p. 14)...